These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38543270)

  • 1. Continuous Microfluidic Antisolvent Crystallization as a Bottom-Up Solution for the Development of Long-Acting Injectable Formulations.
    Nandi S; Verstrepen L; Hugo Silva M; Padrela L; Tajber L; Collas A
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of long-acting injectable suspensions by continuous antisolvent crystallization: An integrated bottom-up process.
    Nandi S; Padrela L; Tajber L; Collas A
    Int J Pharm; 2023 Dec; 648():123550. PubMed ID: 37890647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bottom-up production of injectable itraconazole suspensions using membrane technology.
    Anjum F; Viville T; Nandi S; Wessner M; De Witte B; Collas A; Sadowski G
    Int J Pharm; 2024 Apr; 654():123977. PubMed ID: 38458403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
    Pornputtapitak W; El-Gendy N; Berkland C
    J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking
    Nguyen V; Bevernage J; Darville N; Tistaert C; Van Bocxlaer J; Rossenu S; Vermeulen A
    Mol Pharm; 2021 Mar; 18(3):952-965. PubMed ID: 33400546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of itraconazole nano-co-crystals into multiparticulate oral dosage forms.
    Huang Z; Staufenbiel S; Bodmeier R
    Eur J Pharm Biopharm; 2022 Jul; 176():75-86. PubMed ID: 35598769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailoring the use of excipients in bottom-up production of naproxen crystal suspensions via membrane technology.
    Anjum F; Wessner M; De Witte B; Al-Rifai N; Collas A; Sadowski G
    Int J Pharm; 2024 Mar; 652():123846. PubMed ID: 38272195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.
    Jakubowska E; Milanowski B; Lulek J
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions.
    Bao Q; Zou Y; Wang Y; Choi S; Burgess DJ
    AAPS J; 2021 Mar; 23(2):42. PubMed ID: 33709196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Optimization of Itraconazole-Loaded Solid Lipid Nanoparticles for Topical Administration Using High Shear Homogenization Process by Design of Experiments: In Vitro, Ex Vivo and In Vivo Evaluation.
    Kumar N; Goindi S
    AAPS PharmSciTech; 2021 Oct; 22(7):248. PubMed ID: 34647162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solubility parameter-based screening methods for early-stage formulation development of itraconazole amorphous solid dispersions.
    Piccinni P; Tian Y; McNaughton A; Fraser J; Brown S; Jones DS; Li S; Andrews GP
    J Pharm Pharmacol; 2016 May; 68(5):705-20. PubMed ID: 26864155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
    Parikh T; Sandhu HK; Talele TT; Serajuddin AT
    Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Diagrams of Polymer-Dispersed Liquid Crystal Systems of Itraconazole/Component Immiscibility Induced by Molecular Anisotropy.
    Kozyra A; Mugheirbi NA; Paluch KJ; Garbacz G; Tajber L
    Mol Pharm; 2018 Nov; 15(11):5192-5206. PubMed ID: 30252481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
    Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
    J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles.
    Cheow WS; Kiew TY; Yang Y; Hadinoto K
    Mol Pharm; 2014 May; 11(5):1611-20. PubMed ID: 24669821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Excipients and Seeding on the Solid-State Form Transformation of Indomethacin during Liquid Antisolvent Precipitation.
    Hugo Silva M; Kumar A; Hodnett BK; Tajber L; Holm R; Hudson SP
    Cryst Growth Des; 2022 Oct; 22(10):6056-6069. PubMed ID: 36217420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement.
    Sathigari SK; Ober CA; Sanganwar GP; Gupta RB; Babu RJ
    J Pharm Sci; 2011 Jul; 100(7):2952-65. PubMed ID: 21344415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
    Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranking Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane.
    Tsinman K; Tsinman O; Lingamaneni R; Zhu S; Riebesehl B; Grandeury A; Juhnke M; Van Eerdenbrugh B
    Pharm Res; 2018 Jun; 35(8):161. PubMed ID: 29926245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.